Cargando…

Immunization with the Malaria Diversity-Covering Blood-Stage Vaccine Candidate Plasmodium falciparum Apical Membrane Antigen 1 DiCo in Complex with Its Natural Ligand PfRon2 Does Not Improve the In Vitro Efficacy

The blood-stage malaria vaccine candidate Plasmodium falciparum apical membrane antigen 1 (PfAMA1) can induce strong parasite growth-inhibitory antibody responses in animals but has not achieved the anticipated efficacy in clinical trials. Possible explanations in humans are the insufficient potency...

Descripción completa

Detalles Bibliográficos
Autores principales: Spiegel, Holger, Boes, Alexander, Fendel, Rolf, Reimann, Andreas, Schillberg, Stefan, Fischer, Rainer
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2017
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5484772/
https://www.ncbi.nlm.nih.gov/pubmed/28702028
http://dx.doi.org/10.3389/fimmu.2017.00743
_version_ 1783245934751121408
author Spiegel, Holger
Boes, Alexander
Fendel, Rolf
Reimann, Andreas
Schillberg, Stefan
Fischer, Rainer
author_facet Spiegel, Holger
Boes, Alexander
Fendel, Rolf
Reimann, Andreas
Schillberg, Stefan
Fischer, Rainer
author_sort Spiegel, Holger
collection PubMed
description The blood-stage malaria vaccine candidate Plasmodium falciparum apical membrane antigen 1 (PfAMA1) can induce strong parasite growth-inhibitory antibody responses in animals but has not achieved the anticipated efficacy in clinical trials. Possible explanations in humans are the insufficient potency of the elicited antibody responses, as well as the high degree of sequence polymorphisms found in the field. Several strategies have been developed to improve the cross-strain coverage of PfAMA1-based vaccines, whereas innovative concepts to increase the potency of PfAMA1-specific IgG responses have received little attention even though this may be an essential requirement for protective efficacy. A previous study has demonstrated that immunization with a complex of PyAMA1 and PyRON2, a ligand with an essential functional role in erythrocyte invasion, leads to protection from lethal Plasmodium yoelli challenge in an animal model and suggested to extend this strategy toward improved strain coverage by using multiple PfAMA1 alleles in combination with PfRon2L. As an alternative approach along this line, we decided to use PfRon2L in combination with three PfAMA1 diversity covering variants (DiCo) to investigate the potential of this complex to induce more potent parasite growth inhibitory immune response in combination with better cross-strain-specific efficacy. Within the limits of the study design, the ability of the PfAMA1 DiCo-Mix to induce cross-strain-specific antibodies was not affected in all immunization groups, but the DiCo–PfRon2L complexes did not improve the potency of PfAMA1-specific IgG responses.
format Online
Article
Text
id pubmed-5484772
institution National Center for Biotechnology Information
language English
publishDate 2017
publisher Frontiers Media S.A.
record_format MEDLINE/PubMed
spelling pubmed-54847722017-07-12 Immunization with the Malaria Diversity-Covering Blood-Stage Vaccine Candidate Plasmodium falciparum Apical Membrane Antigen 1 DiCo in Complex with Its Natural Ligand PfRon2 Does Not Improve the In Vitro Efficacy Spiegel, Holger Boes, Alexander Fendel, Rolf Reimann, Andreas Schillberg, Stefan Fischer, Rainer Front Immunol Immunology The blood-stage malaria vaccine candidate Plasmodium falciparum apical membrane antigen 1 (PfAMA1) can induce strong parasite growth-inhibitory antibody responses in animals but has not achieved the anticipated efficacy in clinical trials. Possible explanations in humans are the insufficient potency of the elicited antibody responses, as well as the high degree of sequence polymorphisms found in the field. Several strategies have been developed to improve the cross-strain coverage of PfAMA1-based vaccines, whereas innovative concepts to increase the potency of PfAMA1-specific IgG responses have received little attention even though this may be an essential requirement for protective efficacy. A previous study has demonstrated that immunization with a complex of PyAMA1 and PyRON2, a ligand with an essential functional role in erythrocyte invasion, leads to protection from lethal Plasmodium yoelli challenge in an animal model and suggested to extend this strategy toward improved strain coverage by using multiple PfAMA1 alleles in combination with PfRon2L. As an alternative approach along this line, we decided to use PfRon2L in combination with three PfAMA1 diversity covering variants (DiCo) to investigate the potential of this complex to induce more potent parasite growth inhibitory immune response in combination with better cross-strain-specific efficacy. Within the limits of the study design, the ability of the PfAMA1 DiCo-Mix to induce cross-strain-specific antibodies was not affected in all immunization groups, but the DiCo–PfRon2L complexes did not improve the potency of PfAMA1-specific IgG responses. Frontiers Media S.A. 2017-06-27 /pmc/articles/PMC5484772/ /pubmed/28702028 http://dx.doi.org/10.3389/fimmu.2017.00743 Text en Copyright © 2017 Spiegel, Boes, Fendel, Reimann, Schillberg and Fischer. http://creativecommons.org/licenses/by/4.0/ This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
spellingShingle Immunology
Spiegel, Holger
Boes, Alexander
Fendel, Rolf
Reimann, Andreas
Schillberg, Stefan
Fischer, Rainer
Immunization with the Malaria Diversity-Covering Blood-Stage Vaccine Candidate Plasmodium falciparum Apical Membrane Antigen 1 DiCo in Complex with Its Natural Ligand PfRon2 Does Not Improve the In Vitro Efficacy
title Immunization with the Malaria Diversity-Covering Blood-Stage Vaccine Candidate Plasmodium falciparum Apical Membrane Antigen 1 DiCo in Complex with Its Natural Ligand PfRon2 Does Not Improve the In Vitro Efficacy
title_full Immunization with the Malaria Diversity-Covering Blood-Stage Vaccine Candidate Plasmodium falciparum Apical Membrane Antigen 1 DiCo in Complex with Its Natural Ligand PfRon2 Does Not Improve the In Vitro Efficacy
title_fullStr Immunization with the Malaria Diversity-Covering Blood-Stage Vaccine Candidate Plasmodium falciparum Apical Membrane Antigen 1 DiCo in Complex with Its Natural Ligand PfRon2 Does Not Improve the In Vitro Efficacy
title_full_unstemmed Immunization with the Malaria Diversity-Covering Blood-Stage Vaccine Candidate Plasmodium falciparum Apical Membrane Antigen 1 DiCo in Complex with Its Natural Ligand PfRon2 Does Not Improve the In Vitro Efficacy
title_short Immunization with the Malaria Diversity-Covering Blood-Stage Vaccine Candidate Plasmodium falciparum Apical Membrane Antigen 1 DiCo in Complex with Its Natural Ligand PfRon2 Does Not Improve the In Vitro Efficacy
title_sort immunization with the malaria diversity-covering blood-stage vaccine candidate plasmodium falciparum apical membrane antigen 1 dico in complex with its natural ligand pfron2 does not improve the in vitro efficacy
topic Immunology
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5484772/
https://www.ncbi.nlm.nih.gov/pubmed/28702028
http://dx.doi.org/10.3389/fimmu.2017.00743
work_keys_str_mv AT spiegelholger immunizationwiththemalariadiversitycoveringbloodstagevaccinecandidateplasmodiumfalciparumapicalmembraneantigen1dicoincomplexwithitsnaturalligandpfron2doesnotimprovetheinvitroefficacy
AT boesalexander immunizationwiththemalariadiversitycoveringbloodstagevaccinecandidateplasmodiumfalciparumapicalmembraneantigen1dicoincomplexwithitsnaturalligandpfron2doesnotimprovetheinvitroefficacy
AT fendelrolf immunizationwiththemalariadiversitycoveringbloodstagevaccinecandidateplasmodiumfalciparumapicalmembraneantigen1dicoincomplexwithitsnaturalligandpfron2doesnotimprovetheinvitroefficacy
AT reimannandreas immunizationwiththemalariadiversitycoveringbloodstagevaccinecandidateplasmodiumfalciparumapicalmembraneantigen1dicoincomplexwithitsnaturalligandpfron2doesnotimprovetheinvitroefficacy
AT schillbergstefan immunizationwiththemalariadiversitycoveringbloodstagevaccinecandidateplasmodiumfalciparumapicalmembraneantigen1dicoincomplexwithitsnaturalligandpfron2doesnotimprovetheinvitroefficacy
AT fischerrainer immunizationwiththemalariadiversitycoveringbloodstagevaccinecandidateplasmodiumfalciparumapicalmembraneantigen1dicoincomplexwithitsnaturalligandpfron2doesnotimprovetheinvitroefficacy